Updated Phase 1 dose-escalation data (n=58) show VIR-5500 monotherapy has a favorable safety profile and was well tolerated with no dose-limiting toxicities observed to date - Dose-dependent anti-tumo ...

Cullinan Therapeutics has a robust T-cell engager pipeline, savvy management, and a strong cash position. Read more on what investors should know about the company.

A new CAR T therapy design uses the approved drug venetoclax to temporarily disengage engineered immune cells from tumors.

USFDA accepts for review Dr Reddy's biologics license application for Orencia biosimilar DRL_AB Swati Bharadwaj Hyderabad: Dr Reddy’s Laboratories Ltd.

Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today presented data on its novel ...

Coherus BioSciences shows underwhelming LOQTORZI sales and reliance on upcoming pipeline catalysts. Read why CHRS stock is ...

Among the most promising tools of cancer therapy, engineered immune cells known as chimeric antigen-receptor (CAR) T cells ...

Sift Biosciences, a UC Berkeley spinout developing a next-generation peptide immunotherapy platform that integrates AI, metagenomics, and high-throughput immune profiling, today announced the closing ...

Immunotherapy—which activates the body's own immune system to kill cancer cells—has not worked well against a rare and fatal liver cancer, but a new study finds an existing FDA-approved drug may allow ...

Explore the evolution of T-cell engagers, from experimental concepts to effective therapies for haematologic malignancies.